Friday, 1st September MIN Spring Retreat 2023

• The immune infiltrate in breast cancer and relevance for prognosis and checkpoint inhibition - Sherene Loi
• Immunotherapy using combined anti-PD-1/CTLA-4 checkpoint blockade in rare malignancies – Lessons learned from CA209-538 and Outlook towards MoST-CIRCUIT - Oliver Klein
• The Centre of Excellence in Cellular Immunotherapy at Peter Mac - Jane Oliaro
• Investigation of intestinal cell signalling pathways on local and systemic immunity to cancer - Marina H Yakou
• CAR-DC1: A novel next-generation dendritic cell therapy for targeting solid tumours - Shengbo Zhang
• Epigenetic mechanisms of malignant clonal dominance and immune evasion - Mark Dawson

• Microbiota-induced responsiveness of CD8+ T cells to cancer immunotherapy - Sammy Bedoui
• Immunotherapeutic potential of gamma delta T cells - Jennifer Juno
• Host-directed Treatment to Improve Anti-parasitic Immunity to Malaria - Michelle Boyle
• B cells orchestrate early CD8 T cell priming in response to chronic viral infections - Catarina Gago da Graca
• The Vγ9Vδ2⁺ T cell receptor co-binds butyrophilins 2A1 and 3A1 - Tom S Fulford
• ID3 and c-Kit define the stem-like potential of T cells and their response to chronic infection and cancer - Amania A. Sheikh

• Identifying a novel inflammatory disorder caused by mutation in coatomer complex I - Hongyu HZ Zheng
• Drug targeting of colorectal cancers including cancer stem cells - Reem ALHulais
• Novel pre-conditioning regimens prior to adoptive immunotherapy in mice - Joanne E Davis
• Targeted radiotherapy [177Lu]-PSMA-I&T activates the tumour microenvironment for cellular immunotherapy in patient-derived xenograft models of prostate cancer - Isabel M Everard
• Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in tumour-free mice: consequences for fertility of female cancer survivors - Jordan N Higgins
• Immunological Changes in Marginal Zone Lymphoma Patients Undergoing Combination Therapy with Venetoclax and Ibrutinib: Insights from a Longitudinal Study - Hong Han (Lina) Le
• Uncovering the mechanisms of ovarian damage induced by checkpoint inhibitor immunotherapy - Yasmin M Lewis
• CD28 stimulation enhances CAR T cell differentiation, particularly in older patients, but CD28 abundance is predictive of CAR T cell product quality. - Palak H Mehta
• Overcoming immune checkpoint inhibitor resistance to improve melanoma therapy - Davide Moi
• CRISPR-HDR engineering of T cells for immunotherapy purposes - Maria N. de Menezes
• Activating the endogenous armoury: anticancer drugs as immunotherapy enablers - Hieu Nguyen
• Regulation of exhausted CD8⁺ T cell differentiation by IKZF transcription factors   - Sinead M Reading
• Engineering haematopoietic stem cells for in-situ generation of CAR-NK cells - Kelden Richardson
• Investigating Peripheral CD8+ T cell Tolerance in Colorectal Cancer – the TIPTOE Trial - Sara Roth
• Core fucosylation of IL-15 receptor delineates homeostatic proliferation and apoptosis signalling required for natural killer cell development - Harrison Sudholz
• CD155 PLAYS A DOMINANT ROLE IN MODULATING NK CELL ACTIVATION. - Tania Allin Vargas Pavia
• High-Affinity T Cell Receptor Discovery for Precision Ovarian Cancer T Cell Receptor Therapy - Anusha Yellapragada
• Interleukin-2, not chemokine receptors CXCR3, CXCR5 or CXCR6, controls Th1/Tfh fate bifurcation during blood-stage malaria. - Takahiro Asatsuma
• A deep profiling of the SARS-CoV-2 immunopeptidome with a broad coverage of the viral genome - Asolina Braun
• Antigen uptake and presentation by human lymphoid organ fibroblasts - Zoe Chua
• Evaluating the role of AP-1 transcription factors in CD8+ T cell differentiation and fate - Christian Deo T. Deguit
• mRNA vaccine against malaria tailored for liver-resident memory T cells - Lauren E Holz
• Variation in KIR3DL1-allotype binding to HLA ligands modifies the effects of education and detection of HLA loss - Philippa M Saunders

Please note the bus will depart at 5pm sharp!